Regeneron Pharmaceuticals 8-K

Summary

Collaboration expansion and Q3 2026 charge update. Regeneron and Sanofi agreed to co-develop and co-commercialize four new long-acting antibodies, with an upfront payment and potential milestone payments to Regeneron. They also settled Regeneron’s lawsuit over access to commercialization information and audit rights, and Regeneron agreed to dismiss it.

Key Figures

• Q3 2026 acquired in-process research and development charge: ≈$22M pre-tax; expected to reduce both GAAP and non-GAAP net income per diluted share by ≈$(0.18).
• Collaboration economics: $1.0B upfront payment to Regeneron and up to $7.0B in additional development, regulatory and commercial milestone payments; global profits on the new products shared equally.
• Development costs shared equally; Regeneron is responsible for costs above a budget cap for the new products, subject to certain future recoupment rights.

Guidance

No guidance in this filing.

Investor Takeaways

• Watch for development plans for the other three antibodies and Regeneron’s post-trial decision on whether to add Sanofi’s lunsekimig or another early-development product to the collaboration.